Last quarter (Q3 2023), Xtacy Therapeutics's total revenue was C$―, a decrease of ― from the same quarter last year. In Q3, Xtacy Therapeutics's net income was C$-362.52K. See Xtacy Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Sep 22	Sep 21	Sep 20	Sep 19	Sep 18
Total Revenue	-	-	-	C$ 101.87K	C$ 112.28K	C$ -491.77K
Cost of Revenue	C$ -423.54K	-	C$ 1.51K	-	-	-
Gross Profit	-	-	C$ -1.51K	C$ 101.87K	C$ 112.28K	C$ -491.77K
Operating Expense	C$ 1.13M	C$ 1.38M	C$ 3.88M	C$ 698.26K	C$ 2.82M	C$ 2.81M
Operating Income	C$ -1.31M	C$ -1.38M	C$ -3.88M	C$ -594.44K	C$ -2.71M	C$ -3.30M
Net Non Operating Interest Income Expense	C$ -10.93K	C$ -4.59K	C$ 1.57K	C$ 1.95K	C$ 2.62K	C$ 1.49K
Other Income Expense	C$ -48.28K	C$ -11.43K	C$ 298.05K	C$ -778.60K	C$ 338.14K	C$ -449.00K
Pretax Income	C$ -1.27M	C$ -1.37M	C$ -3.58M	C$ -1.37M	C$ -2.37M	C$ -3.75M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	C$ -1.27M	C$ -1.37M	C$ -3.58M	C$ -1.37M	C$ -2.37M	C$ -3.75M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	C$ 706.95K	C$ 1.38M	-	-	-	-
Interest Expense	-	-	-	-	-	-
Net Income From Continuing And Discontinued Operation	C$ -1.27M	C$ -1.37M	C$ -3.58M	C$ -1.37M	C$ -2.37M	C$ -3.75M
Normalized Income	C$ -1.43M	C$ -1.01M	C$ -2.93M	C$ 712.81K	C$ -1.81M	C$ -1.86M
EBIT	C$ -1.26M	C$ -1.36M	C$ -3.58M	C$ -1.37M	C$ -2.53M	C$ -3.75M
EBITDA	C$ -1.26M	C$ -1.36M	C$ -3.58M	C$ -1.37M	C$ -2.53M	C$ -3.75M

Currency in CAD

Xtacy Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing